Nebraska LR 379: Interim study to examine the role of health insurance for biomarker testing and the use of biomarker testing in public and private payor markets

Status: Referred to Banking, Commerce and Insurance Committee (as of 2024-04-05)

State: Nebraska · Session: 108 · Bill: LR 379

Sponsors: Bostar

View Nebraska LR 379 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.